Bremer Bank National Association Makes New Investment in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Bremer Bank National Association bought a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the 4th quarter, Holdings Channel.com reports. The fund bought 63,833 shares of the company’s stock, valued at approximately $4,990,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Community Bank of Raymore increased its position in shares of GE HealthCare Technologies by 18.3% in the 4th quarter. Community Bank of Raymore now owns 14,813 shares of the company’s stock worth $1,158,000 after purchasing an additional 2,296 shares during the last quarter. Hall Laurie J Trustee increased its position in shares of GE HealthCare Technologies by 13.5% in the 4th quarter. Hall Laurie J Trustee now owns 2,742 shares of the company’s stock worth $214,000 after purchasing an additional 327 shares during the last quarter. Artemis Investment Management LLP increased its position in shares of GE HealthCare Technologies by 15.4% in the 4th quarter. Artemis Investment Management LLP now owns 59,472 shares of the company’s stock worth $4,650,000 after purchasing an additional 7,937 shares during the last quarter. Herbst Group LLC increased its position in shares of GE HealthCare Technologies by 25.4% in the 4th quarter. Herbst Group LLC now owns 23,190 shares of the company’s stock worth $1,813,000 after purchasing an additional 4,690 shares during the last quarter. Finally, HB Wealth Management LLC grew its position in shares of GE HealthCare Technologies by 24.5% during the 4th quarter. HB Wealth Management LLC now owns 8,366 shares of the company’s stock valued at $654,000 after buying an additional 1,645 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Activity at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Trading Down 0.3 %

Shares of NASDAQ:GEHC opened at $84.74 on Monday. The company has a 50 day moving average of $81.98 and a 200-day moving average of $84.43. The firm has a market cap of $38.72 billion, a P/E ratio of 23.28, a P/E/G ratio of 2.80 and a beta of 1.11. GE HealthCare Technologies Inc. has a twelve month low of $71.31 and a twelve month high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.99 EPS. As a group, analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. The ex-dividend date is Tuesday, January 14th. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a yield of 0.17%. GE HealthCare Technologies’s dividend payout ratio is currently 3.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Stifel Nicolaus boosted their price objective on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, Evercore ISI upped their target price on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.00.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.